Infliximab therapy for HIV positive Crohn's disease: A case report
Syed F Habib1, Muhammad Z Hasan, I Salam
1West Wales General Hospital, Carmarthen SA31 2EE, United Kingdom.
Journal of Crohn'S & Colitis
|December 22, 2010
Summary
This study details the first successful use of infliximab for Crohn's disease in an HIV-positive patient not receiving antiretroviral therapy. It addresses safety concerns regarding anti-tumor necrosis factor-alpha (TNF-alpha) therapy in this population.
Area of Science:
- Gastroenterology and Immunology
- Infectious Diseases
Background:
- Anti-tumor necrosis factor-alpha (TNF-alpha) agents are standard for Crohn's disease.
- Limited data exists on anti-TNF-alpha use in HIV-positive Crohn's patients.
- Previous reports include one case on antiretroviral therapy.
Purpose of the Study:
- To report the first successful use of infliximab in an HIV-positive Crohn's disease patient without antiretroviral treatment.
- To explore the safety and efficacy of infliximab in this specific patient group.
Main Methods:
- Case report of an HIV-positive patient with Crohn's disease.
- Treatment with infliximab without concomitant antiretroviral therapy.
- Monitoring of disease activity and patient well-being.
Main Results:
- Successful treatment of Crohn's disease symptoms with infliximab.
- No adverse events reported related to infliximab use in the context of HIV.
- Demonstrated efficacy in a patient not on antiretroviral therapy.
Conclusions:
- Infliximab can be successfully used to treat Crohn's disease in HIV-positive patients, even without antiretroviral therapy.
- This finding challenges apprehension regarding anti-TNF-alpha use in HIV-positive individuals.
- Further research is warranted to confirm safety and efficacy in broader populations.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...